A click chemistry approach to pleuromutilin derivatives, evaluation of anti-MRSA activity and elucidation of binding mode by surface plasmon resonance and molecular docking.

J Enzyme Inhib Med Chem

Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.

Published: December 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Novel series of pleuromutilin analogs containing substituted 1,2,3-triazole moieties were designed, synthesised and assessed for their antibacterial activity against Methicillin-resistant (MRSA). Initially, the antibacterial activities of these derivatives against 4 strains of (MRSA ATCC 43300, ATCC 29213, AD3, and 144) were tested by the broth dilution method. Most of the synthesised pleuromutilin analogs displayed potent activities. Among them, compounds , , and (MIC = 0.5∼1 µg/mL) showed the most effective antibacterial activity and their anti-MRSA activity were further studied by the time-killing kinetics approach. Binding mode investigations by surface plasmon resonance (SPR) with ribosome revealed that the selected compounds all showed obvious affinity for ribosome (K = 2.32 × 10∼5.10 × 10 M). Subsequently, the binding of compounds and to the ribosome was further investigated by molecular modelling. Compound had a superior docking mode with ribosome, and the binding free energy of compound was calculated to be -12.0 kcal/mol.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635623PMC
http://dx.doi.org/10.1080/14756366.2021.1977931DOI Listing

Publication Analysis

Top Keywords

anti-mrsa activity
8
binding mode
8
surface plasmon
8
plasmon resonance
8
pleuromutilin analogs
8
antibacterial activity
8
click chemistry
4
chemistry approach
4
approach pleuromutilin
4
pleuromutilin derivatives
4

Similar Publications

With the continued upsurge of antibiotic resistance and reduced susceptibility to almost all frontline antibiotics, there is a pressing need for the development of new, effective, and safe alternatives. In this study, a scaffold-hopping strategy was utilized to develop a novel class of penicillin-binding protein 2a (PBP2a) inhibitors, centered around a 4H-chromen-4-one core structure. These newly designed compounds demonstrated strong antibacterial efficacy against methicillin-resistant Staphylococcus aureus (MRSA) and other drug-resistant gram-positive pathogens.

View Article and Find Full Text PDF

Discovery of novel xanthotoxin-pyridine quaternary ammonium derivatives with membrane-targeting mode of action as potential antimicrobials against methicillin-resistant Staphylococcus aureus.

Eur J Med Chem

September 2025

Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan Province, China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan Province,

Methicillin-resistant Staphylococcus aureus (MRSA) is a major global health threat owing to its multi-drug resistance, creating an urgent need for novel antibiotics. This study focused on developing anti-MRSA agents by designing and synthesizing 30 xanthotoxin-pyridine quaternary ammonium derivatives, followed by evaluating their antibacterial activity and dissecting their mechanism of action against MRSA. Among all derivatives, III13 demonstrated as the most promising candidate: it exhibited potent anti-MRSA activity (MIC = 1 μg/mL), low cytotoxicity, minimal hemolysis, rapid bactericidal effects, and the ability to disrupt biofilms.

View Article and Find Full Text PDF

Discovery of benzopyronyl imidazolidinediones as new structural skeleton of potential multitargeting antibacterial agents.

Bioorg Chem

August 2025

Institute of Bioorganic & Medicinal Chemistry, Key Laboratory of Applied Chemistry of Chongqing Municipality, School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, China. Electronic address:

This work developed a class of unique benzopyronyl imidazolidinediones (BIs) as new structural skeleton of potential multitargeting antibacterial agents to confront dreadful Staphylococcus aureus infections. Some target compounds exhibited effective antibacterial activities against the tested strains. Especially, butyl BI 6c and 5-hydroxy BI 26d exerted excellent inhibitory activity toward Staphylococcus aureus ATCC 25923 and MRSA 43300 with a low MIC value of 0.

View Article and Find Full Text PDF

Proteomic insights into the multi-target mechanism and therapeutic application of citronellol-loaded carboxymethyl chitosan-based hydrogel for wound infection treatment.

Int J Biol Macromol

August 2025

State Key Laboratory of Bio-based Fiber Materials, National Engineering Lab for Textile Fiber Materials and Processing Technology, School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou 310018, PR China. Electronic address:

Methicillin-resistant Staphylococcus aureus (MRSA) continues to challenge wound care due to its strong biofilm-forming ability and resistance to conventional antibiotics. In this study, we developed a novel multifunctional hydrogel by incorporating citronellol, a bioactive monoterpenoid, into a carboxymethyl chitosan-hyaluronic acid (CMCS-HA) matrix, yielding a biocompatible platform with potent anti-MRSA activity. Unlike many previous phytocompound-based hydrogels, our work provides in-depth mechanistic insights into citronellol's antibacterial and antivirulence actions through proteomics coupled with STRING network analysis.

View Article and Find Full Text PDF

With rising antimicrobial resistance and continuous failure of conventional therapies, innovative drug development against methicillin-resistant Staphylococcus aureus (MRSA) is crucial for effective clinical treatment. Here, new dimethyl quaternary ammonium salt 5b derived from harmane were designed, exhibiting potent anti-MRSA activities including clinical strains (MIC = 0.25-0.

View Article and Find Full Text PDF